September 8, 2003 There could be additional upside with Tularik’s/NASDAQ:  TLRK share price with the anticipation of clinical updates on four of its drugs in the fourth quarter of 2003 and the first half of 2004.

Tularik’s clinical development is on track to enroll the first 100 patients for a total of 750 total worldwide for T67 for liver cancer in a pivotal trial by year-end. The company will give an enrollment update by year-end and expects to present interim safety/efficacy data in mid-2004. The primary endpoint is survival and surrogate endpoints response rate, time to progression, and reduction in alpha-fetal protein, and quality of life will also be monitored. Currently there are no approved drugs for liver cancer, therefore Tularik may seek accelerated approval for T67 if the drug shows significant benefit based on surrogate endpoints from the first 100 patients.

In July, the company initiated Phase II trials for T607 for liver cancer, ovarian cancer, gastric cancer, and esophageal cancer. The endpoint for each of the T607 trials is radiological response rate. By the end of 2003, Phase II trials should be completed and the results presented possibly at ASCO 2004.

On January 24, 2003, Tularik initiated a multiple dose Phase I trial in healthy individuals in the United Kingdom of T131, a potent and orally active insulin sensitizer for the potential treatment of Type II diabetes. If results are positive, a Phase II trial could be initiated as early as the fourth quarter of 2003.

Finally, Tularik completed the single dose portion of the T487 Phase I trial in healthy patients and has recently initiated the multiple dose portion of the study. The company expects to initiate proof-of-concept Phase II trials in rheumatoid arthritis and psoriasis patients in the fourth quarter of 2003.

With four drugs in clinical development and barring any unforeseen events, Tularik is sure to bring at least one drug to market, which will improve the company’s revenue stream and bring a smile to investors faces.

DISCLAIMER
The above information transmitted via BioPortfolio has been provided by the original publishers Nadine Wong of Wong & Wong Inc the publishers of the Biotech Stock Report and http://www.biostockreport.com  ("BSN") a financial information, news, and software service focusing on event-driven biotechnology and pharmaceutical research. The Service is provided by Nadine Wong of Wong & Wong Inc ("NWWW"). 

It is not guaranteed as to completeness or accuracy by BioPortfolio, the BSN publishers, or any person. Such Information is neither an offer to sell nor a solicitation to buy the securities of any company. Opinions expressed are subject to change without notice. The Information and views provided by BSN are prepared by BSN employees and in no way reflect the views or efforts of BioPortfolio Limited., any of BioPortfolio's employees or officers. BioPortfolio, and BioPortfolio's employees and officers, as well as BSN’s employees and officers, in no way accept responsibility for any of the BSN content published on www.bioportfolio.com/. 

While all reasonable care has been taken to ensure that the Information contained herein is presented in good faith, and is not untrue or misleading at the time of publication, BioPortfolio, and BSN make no representation as to its accuracy or completeness and it should not be relied upon as such. The Information is supplied on the condition that the reader or any other person receiving the Information will make his or her own determination as to its suitability for any purpose prior to any use of the Information. From time to time, BioPortfolio and any officers or employees of BioPortfolio, as well as BSN, and any officers or employees of BSN, may, to the extent permitted by law, have a position or otherwise be interested in any transactions, in any investments (including derivatives) directly or indirectly the subject of this report. Also BioPortfolio and BSN may, from time to time solicit business from any company mentioned in this report. This report is provided solely for the information of viewers of BioPortfolio and/or viewers and subscribers of BSN and BioPortfolio information services, who are expected to make their own investment decisions without reliance on this report. Neither BioPortfolio nor any officer or employee of BioPortfolio, nor BSN, or any officer or employee of BSN, accepts any liability whatsoever for any direct, indirect, special or consequential damages or loss arising from any use of this report or their contents. This report may not be reproduced, distributed or published by any recipient for any purpose without the prior express consent of the publishers. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent, trademark or copyright of BioPortfolio, BSN or any third party. 

The value of the investment(s) to which this report relates and their income yield(s) may go up or down. The investment(s) referred to in this report may not be suitable for private investors: if you are in any doubt you should seek advice from your investment advisor. Changes in rates of currency exchange may have an adverse effect on the value, price or income of investments. Statements as to past performance of any investment are not a guide to future performance. The levels and bases of taxation can change, and if you are in doubt you should seek independent professional advice. In some cases it may be difficult for you to sell or realize your investment or to obtain reliable information about its value or the extent of the risks to which you are exposed. 

THIS INFORMATION IS PROVIDED "AS IS" AND NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED OF ACCURACY, MERCHANTIBILITY FITNESS FOR A PARTICULAR PURPOSE OR OF ANY OTHER NATURE ARE MADE WITH RESPECT TO THIS INFORMATION OR TO ANY EXPRESSED VIEWS PRESENTED IN THIS INFORMATION.